Biotech Essentials

Companies & Industries

Biotech Companies & Industries Essentials publishes only the best Biotech news and links, carefully hand-picked and curated by top biotech experts.

Biotech Essentials

Top news of the week: 22.04.2021.

#COVID19
#pandemic
#IPO
#pharma
#Coronavirus
#India
#Biobanks

Companies And Industries

@biospace shared
On Apr 19, 2021
COVID-19 Brief: An inhaled COVID-19 vaccine, expanded antibody access, and blood clots #pandemic #COVID19 https://t.co/c4xXMbK5dL
Open
COVID-19 Brief: An Inhaled COVID-19 Vaccine, Expanded Antibody Access and Blood Clots

COVID-19 Brief: An Inhaled COVID-19 Vaccine, Expanded Antibody Access and Blood Clots

As the U.S. reports surges in COVID-19 infections despite increased enrollment in vaccines, news continues to break about therapies, vaccines, and the risks involved with the new vaccines. ...

@pharmaphorum shared
On Apr 22, 2021
.@Centessa has announced plans for a $100m US IPO just weeks after the company launched with $250m in private backing and an R&D powerhouse driven by the merger of 10 biotechs https://t.co/NzWnXAldiw #IPO #pharma
Open
Centessa plans $100m IPO to fund R&D and potential acquisitions

Centessa plans $100m IPO to fund R&D and potential acquisitions

Centessa has announced plans for a $100m US IPO just weeks after the company launched with $250m with private backing and an R&D powerhouse driven by the merger of 10 biotechs.

@BIRAC_2012 shared
On Apr 16, 2021
RT @ICGEBBioenergy: DBT-ICGEB Centre is working towards translation research and making pitch for its key technologies in association with @venture_center for more details on our research pls visit https://t.co/HObHzmpWkO @shams_yazdani @ICGEB @ICGEBNewDelhi @DBTIndia @BIRAC_2012 @barsebrajesh https://t.co/EbCMuGGR1z
Open
Four Pillars of Our Research

Four Pillars of Our Research

In our effort to develop cost effective process to produce second generation biofuels, we are isolating novel enzymes with higher specificities towards cellulosic biomass. We have …

@FierceBiotech shared
On Apr 16, 2021
If all goes to plan, the deal will close in the third quarter and the combined company will receive $92 million from the SPAC, as well as $120 million through a private round https://t.co/jzrw4Rg50v
Open
Regenerative medicine biotech Surrozen aims for the Nasdaq in $212M SPAC deal

Regenerative medicine biotech Surrozen aims for the Nasdaq in $212M SPAC deal

After banking two $50 million venture rounds about a year apart, Surrozen is ready to hit Wall Street. The company plans to go public via SPAC in a deal worth up to $212 million. ...

@pharmaphorum shared
On Apr 19, 2021
The UK’s unique offering as a life sciences research hub helped convince US biotech @Novavax to develop its COVID-19 jab in the country, according to the head of the Vaccine Taskforce https://t.co/5U9eKd9KbU https://t.co/QQViUin4Eq
Open
UK Vaccine Taskforce head lifts lid on Novavax deal

UK Vaccine Taskforce head lifts lid on Novavax deal

The UK’s unique offering as life sciences research hub helped convince US biotech Novavax to develop its COVID-19 jab in the UK, according to the head of the country’s vaccines task force.

@kiranshaw shared
On Apr 19, 2021
RT @moneycontrolcom: .@Bioconlimited chief @kiranshaw in conversation with @chandrarsrikant on the factors that led to India dropping the ball in its fight against COVID-19 & the solutions ahead. Read: https://t.co/y0GyYWa6jq #COVID19 #Coronavirus #India https://t.co/GVbVPPBiq9
Open
We will have an abundant supply of Remdesivir by the second week of May: Biocon chief Kiran Mazumdar Shaw

We will have an abundant supply of Remdesivir by the second week of May: Biocon chief Kiran Mazumdar Shaw

Biocon Executive Chairperson Kiran Mazumdar Shaw says scarcity of critical anti-COVID-19 drugs Remdesivir and Itolizumab will end in 4-6 weeks as suppliers like her own company ramp up ...

@biobankingcom shared
On Apr 19, 2021
#Biobanks: A Platform for Modern Biomedical Research - by @ShonaliPaul , COO at @CloudLIMS https://t.co/Z7uxn9xjAE
Open
Biobanks – A Platform for Modern Biomedical Research

Biobanks – A Platform for Modern Biomedical Research

Learn why biobanks are indispensable for biomedical research and how biospecimen management LIMS software enables biobanks to securely manage data, meet compliance and enhance operational ...

@matthewherper shared
On Apr 22, 2021
Bluebird talks in Germany may be bad omen for gene therapy in Europe, ⁦@adamfeuerstein⁩ writes. https://t.co/NEhTzmpZdM
Open
Bluebird’s withdrawal of therapy from Germany could chill talks over gene therapy prices across Europe

Bluebird’s withdrawal of therapy from Germany could chill talks over gene therapy prices across Europe

A stalemate in Germany raises broader questions about whether Europe can ever become a viable commercial market for gene therapies.

Read more: Companies And Industries
weekly 22.04.2021
View archives
Back to home

Subscribe to Biotech Essentials - Companies & Industries.

Avoid an information overload and get the most trusted industry news hand-picked by the top Experts. Sign up for the weekly Biotech Essentials - Companies & Industries.
Privacy Policy

Sign up for the weekly Biotech Essentials - Companies & Industries newsletter

Never again miss anything or anyone that matter in Biotech Essentials

Sign up and receive the Biotech Essentials - Companies & Industries weekly email newsletter directly to your inbox. Make more informed business decisions based on insight for the most trusted industry experts, faster.
Privacy Policy